The drug already received Fast Track designation in July 2024, expediting the review process due to its potential to address an unmet medical need.
This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations work...
Tonix Pharmaceuticals hires Bradley Raudabaugh and Errol Gould to enhance marketing and medical affairs ahead of TNX-102 SL FDA review.Quiver AI SummaryTonix Pharmaceuticals has announced the appointment...
Tonix Pharmaceuticals will present at NobleCon20 and conduct investor meetings in December 2024 in Boca Raton, Florida.Quiver AI SummaryTonix Pharmaceuticals Holding Corp. announced that Jessica Morris,...
Tonix Pharmaceuticals presented Phase 3 RESILIENT study results for TNX-102 SL, showing significant improvements in fibromyalgia symptoms. NDA submitted to FDA.Quiver AI SummaryTonix Pharmaceuticals presented...